We Are Crinetics
Crinetics is a pharmaceutical company founded in endocrinology research. Our intense focus is on developing much-needed therapies for people with endocrine diseases and endocrine-related tumors. For us, it’s all about these underserved patients, who are eager to find therapies that provide effective disease control and bring more simplicity to their lives. To better achieve these goals, we also partner with endocrinologists and other healthcare practitioners to ensure we’re solving real problems for them.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Session SP002: June 15, 10:00 AM - 11:00 AMW-375A (ENDO Main Stage)
Crinetics CEO Scott Struthers, Ph.D., accepts the John D. Baxter Prize for Entrepreneurship and presents on the "Adventures Discovering Nonpeptide Oral Drugs Acting at Peptide Hormone Receptors".
Oral Once-Daily, Paltusotine (Non-Peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy in Patients With Acromegaly is Associated With Long-Term Biochemical and Symptom Control and is Preferred Over Injectable Somatostatin-Receptor Ligands
Oral presentation by: Monica Gadelha, MD, PhD
Session OR01: June, 15 10:00 AM – 10:15 am | W-175
Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oral Paltusotine, a Non-Peptide, Selective Somatostatin Receptor Subtype 2 Agonist
Rosa Luo, MS; Alessandra Casagrande, MD, PhD; Sonic Oun, BA; Yang Wang, MSPH; R. Scott Struthers, PhD; Alan Krasner, MD
Crinetics Pharmaceuticals Inc., San Diego, CA, USA
The Use of Salivary Cortisol Measurement by Mass Spectrometry to Identify Low Serum Cortisol Values in Healthy Volunteers Receiving CRN04894, A Melanocortin 2 Receptor (MC2R) Antagonist
Alejandro Ayala, MD; Carl LaCerte, MS; Rosa Luo, MS; Christopher Davidson, MS; Jian Wang, PhD; Peter Trainer, MD; Alan Krasner, MD
Crinetics Pharmaceuticals Inc., San Diego, CA, USA
Discovery and Characterization of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists for the Treatment of Graves’ Disease
Melissa A. Fowler, Collin Regan, Jian Zhao, Eulalia Coutinho, Beth Fleck, Michael Johns, Yang Tang, Emmanuel Sturchler, Mi Chen, Kelsey Retting, Deepak Dalvie, Stephen F. Betz, Stacy Markison
Crinetics Pharmaceuticals, San Diego, CA
Effects of an Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist in Rodent Models of Primary Hyperparathyroidism (PHPT)
Agnes S. Antwan, Elizabeth Rico-Bautista, Joseph Pontillo, Shimiao Wang, Michael A .Johns, Bastian Ramms, Melissa A. Fowler, Julie B. Nguyen, Anel A. Castellanos Gonzalez, Beth Fleck, Kelsey Retting, Deepak Dalvie, Stephen F. Betz, Stacy Markison
Crinetics Pharmaceuticals, San Diego, CA.
Connect With Us
Please complete this form to be contacted directly by a member of our medical affairs team.